Epidemiology studies demonstrate that an increased number of C. difficile-associated outbreaks have been reported worldwide, some with increased mortality and morbidity. This pathogen is the major cause of antibiotic-associated diarrhea (AAD) and pseudomembranous colitis. The diagnosis of toxigenic C. difficile is usually done by tissue culture cytotoxicity assay and/or by C. difficile culture identification and/or by enzyme immunoassay (EIA). The tissue culture cytotoxicity assay and C. difficile culture identification are laborious and time consuming, and results are obtained within 3-5 days. Toxin EIA assays display low sensitivity. Molecular amplification techniques (PCR) allow the detection of only a few copies of bacterial DNA in clinical samples, better sensitivity and specificity. In addition, rapid PCR technology can achieve this in about 3 hours. The combination of these characteristics may allow the prompt targeted treatment of C. difficile-associated disease (CDAD) patients and thus a potential improved patient outcome and reduced recovery time.
Transfer liquid or soft stool (but not urine) into the container.
Avoid mixing toilet paper, or soap with the sample.
Store sample refrigerated until shipment.
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
Reject Criteria: Specimen other than liquid or semi-formed stool; Stool in preservative or mixed with urine; Specimen in wrong transport container